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Abstract
Background:  Neuroblastoma, a frequently occurring solid tumour in children, remains a
therapeutic challenge as existing imaging tools are inadequate for proper and accurate diagnosis,
resulting in treatment failures. Nanoparticles have recently been introduced to the field of cancer
research and promise remarkable improvements in diagnostics, targeting and drug delivery. Among
these nanoparticles, quantum dots (QDs) are highly appealing due to their manipulatable surfaces,
yielding multifunctional QDs applicable in different biological models. The biocompatibility of these
QDs, however, remains questionable.
Results: We show here that QD surface modifications with N-acetylcysteine (NAC) alter QD
physical and biological properties. In human neuroblastoma (SH-SY5Y) cells, NAC modified QDs
were internalized to a lesser extent and were less cytotoxic than unmodified QDs. Cytotoxicity
was correlated with Fas upregulation on the surface of treated cells. Alongside the increased
expression of Fas, QD treated cells had increased membrane lipid peroxidation, as measured by
the fluorescent BODIPY-C11 dye. Moreover, peroxidized lipids were detected at the mitochondrial
level, contributing to the impairment of mitochondrial functions as shown by the MTT reduction
assay and imaged with confocal microscopy using the fluorescent JC-1 dye.
Conclusion: QD core and surface compositions, as well as QD stability, all influence nanoparticle
internalization and the consequent cytotoxicity. Cadmium telluride QD-induced toxicity involves
the upregulation of the Fas receptor and lipid peroxidation, leading to impaired neuroblastoma cell
functions. Further improvements of nanoparticles and our understanding of the underlying
mechanisms of QD-toxicity are critical for the development of new nanotherapeutics or
diagnostics in nano-oncology.
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Background
Neuroblastoma is the most frequently occurring extracra-
nial solid tumour in children, accounting for 9% of all
childhood cancers, with poor prognosis [1]. This malig-
nant tumour arises from neuroepithelial cells of the sym-
pathetic nervous system early in development, and is
typically found in the adrenal medulla, abdomen, chest or
neck [2]. Neuroblastoma, however, remains a therapeutic
challenge as current surgical and chemical treatments are
insufficient to prevent tumour recurrence, metastasis and
progression [3]. Accurate disease staging is critical for
appropriate therapeutic intervention, but existing imaging
tools are still lacking in early and accurate diagnosis [4].
The introduction of nanoparticles in the field of cancer
research has recently improved diagnosis, targeting and
drug delivery with the use of nanotubes, liposomes, den-
drimers and polymers [5-7]. Other nanoparticles, such as
quantum dots, possess excellent photophysical properties
and prove to be an elegant alternative to the traditional
bioimaging tools [8]. Quantum dots (QDs) are one of the
most rapidly evolving products of nanotechnology, with
great potential as a tool for biomedical and bioanalytical
imaging. Their superior photophysical properties [9] and
sometimes multifunctional surfaces are suitable for appli-
cations in various biological models [10]. A study by the
Nie group describes the application of these multifunc-
tional QDs for in vivo imaging and targeting of breast and
prostate cancers [11]. Although the development of QDs
as bioimaging tools may be well underway, their potential
application as therapeutic agents is yet to be explored.
Biological media, intracellular microenvironment and
different enzymatic systems could destabilize originally
well protected QD surfaces yielding more cytotoxic nano-
particles [12,13]. Uncoated or weakly stabilized cadmium
telluride QDs produce significant amounts of reactive
oxygen species in vitro [12], and induce death in various
cell types [14,15].
Oxidative stress-induced cell death, both apoptosis and
necrosis, can involve a number of cellular mechanisms,
one of which includes the activation of Fas receptor
[16,17]. Fas (CD95) belongs to the family of tumour
necrosis factor receptors, and is a prototypical "death
receptor." In the immune system, it regulates cell numbers
by inducing apoptosis, and is involved in T cell-mediated
cytotoxicity. It can also induce neuronal cell death [18-
21]. Activation of Fas receptor by Fas ligand recruits the
Fas-Associated Death Domain (FADD) to the Death
Domain in the cytoplasmic tail of the receptor, and can
lead to caspase activation and cell death [22]. Down-
stream signaling of Fas can also induce activation of
lipases and pro-apoptotic transcription factors like p53,
which then potentiate apoptosis [23].
Oxidative stress can also induce other levels of cell mem-
brane damage, including membrane lipid peroxidation
[24]. Free radicals induce the cleavage of membrane lip-
ids, resulting in the production of aldehydes, reinforcing
cellular stress. Intracellular lipid peroxidation can also
occur at the level of the organelle membranes, especially
at the membranes of the highly metabolically active mito-
chondria. Mitochondria regulate crucial cellular processes
including adenosine triphosphate (ATP) production,
intracellular pH regulation and neuronal-glial interac-
tions [25]. Many neurodegenerative diseases, including
Parkinson's and Alzheimer's diseases, involve the mal-
functioning of the mitochondria, seen as decreased mito-
chondrial activity, decreased ATP production or loss of
mitochondrial membrane potential (∆ψm) [25].
In this study, we explored mechanisms of QD-induced
toxicity in a human neuroblastoma cell line exposed to
cysteamine-QDs and QDs modified by an antioxidant, N-
acetylcysteine. We report new mechanisms of cytotoxicity
induced by these QDs, including the i) upregulation of
the Fas receptor, ii) lipid peroxidation, and iii) impaired
mitochondrial function. Understanding the mechanisms
underlying QD-toxicity will provide alternative ways of
nanoparticle manipulations to make them more suitable
tools in nanomedicine, specifically nano-oncology.
Results
Surface modifications of cadmium telluride QDs with N-
acetylcysteine
To investigate mechanisms underlying cell death induced
by cadmium telluride (CdTe) QDs, we modified the sur-
face of cysteamine-capped CdTe QDs with an antioxidant,
N-acetylcysteine (NAC, Figure 1b), a drug which has been
found previously to protect cells against oxidative stress
and QD-induced cytotoxicity [14]. Cysteamine-capped
(''unmodified'') QDs (Figure 1a) have amino groups at
the surface and are positively charged (+14.2 mV). Cova-
lent binding of NAC to cysteamine on the QD surface
(Figure 1c) yielded NAC-conjugated QDs with a decreased
net surface charge, and charge-charge complexation of
NAC and cysteamine yielded NAC-capped QDs with car-
boxylic groups on the surface and a net negative charge of
-9.8 mV (Figure 1d). Spectrofluorometric measurements
revealed marked differences in the fluorescence intensities
and QD stability in different media (see Additional file 1).
In phosphate buffered saline (PBS), cysteamine-QDs
show a red-shift with time but no change in fluorescence
intensity, whereas, NAC-conjugated QDs decreased in flu-
orescence with time. NAC-capped QDs were the most sta-
ble in PBS, with no spectral shift and no loss of
fluorescence within 24 hours.Journal of Nanobiotechnology 2007, 5:1 http://www.jnanobiotechnology.com/content/5/1/1
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Schematic representations of unmodified and NAC-modified QDs Figure 1
Schematic representations of unmodified and NAC-modified QDs. a. cysteamine-capped ("unmodified") QD (λem = 
542 nm in water), b. N-acetylcysteine (NAC) c. NAC-conjugated QD (λem = 526 nm in water), d. NAC-capped QD (λem = 528 
nm in water).
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Cytotoxicity of NAC-modified CdTe QDs in 
neuroblastomas
To examine the cytotoxicity of cysteamine-QDs and NAC-
modified QDs, we assessed the viability of SH-SY5Y
human neuroblastoma cells by fluorescence-activated cell
scanning (FACS), and their mitochondrial metabolism
using a MTT reduction assay. Our FACS data show that
cells exposed to 5 µg/mL of cysteamine-QDs, NAC-conju-
gated or NAC-capped QDs yielded distinct populations of
dead cells (Figure 2a), suggesting significant toxicity
induced by these QDs. Significantly less viability was
observed in cells treated with cysteamine-QDs (52.2 ±
0.7%, p < 0.05) when compared to untreated control cells
in serum-free medium (75.9 ± 9.1%). It is noteworthy
that trophic factor deprivation, due to serum withdrawal,
contributes to cell death which explains the approxi-
mately 25% decrease in viability in the absence of QDs
(i.e. untreated control). NAC treatment can rescue cells in
this trophic factor withdrawal paradigm [26]. QD-
induced cytotoxicity is prevented with cell pretreatment
with 2 mM NAC (85.5 ± 5.7%; p < 0.01; Figure 2b), con-
firming and complementing results from our previous
studies demonstrating the effectiveness of NAC against
both trophic factor deprivation and additional QD-insult
[14]. These multiple insults to neuroblastoma cells lead to
cell death both by apoptosis and necrosis. The latter is
characterized by mitochondrial and lysosomal swelling
and perinuclear localization of these organelles [17].
NAC-capped and NAC-conjugated QDs are still cytotoxic
(65.6 ± 5.0%, p < 0.05 and 59.1 ± 5.1%, p < 0.05 respec-
tively) compared to control.
Results of the FACS analyses were corroborated by data
from measuring cellular MTT reduction (Figure 2c). Mito-
chondrial metabolic activity was most significantly
reduced in cells in the presence of cysteamine-QDs (50.1
± 5.2%; p < 0.01). NAC-conjugated QDs also significantly
reduced the cellular mitochondrial activity (62.3 ± 6.5%;
p < 0.01) compared to control. Cells treated with NAC-
capped QDs, on the other hand, suffered less cytotoxic
damage and showed significantly higher mitochondrial
metabolic activity (90.2 ± 2.2%; p < 0.01) compared to
cells treated with cysteamine-QDs or NAC-conjugated
QDs. Cells pretreated with NAC, prior to cysteamine-QD
addition, show significantly higher activity (106.1 ±
11.8%; p  < 0.01) when compared to QD-treated cells,
again reinforcing the protective role of free NAC against
QD-induced toxicity.
Upregulation of Fas at the cell surface and internalization 
of QDs by neuroblastoma cells
QD-induced cytotoxicity involves oxidative stress, specifi-
cally via the production of reactive oxygen species (ROS)
[12,15]. One cell-damaging, downstream effect of ROS
production is the upregulation of the cell surface Fas
receptor. FACS analyses revealed significant upregulation
of Fas expression on the surface of SH-SY5Y cells treated
with cysteamine-QDs (net mean fluorescence intensity
(MFI) is 64.3 ± 5.5, p < 0.05) and NAC-conjugated QDs
(net MFI = 57.1 ± 3.7, p  < 0.05) when compared to
untreated control cells (net MFI = 43.9 ± 1.1; Figures 3a
and 3b). No upregulation of Fas was observed in cells
treated with NAC-capped QDs (net MFI = 42.1 ± 3.7), and
Fas upregulation was completely inhibited in cells pre-
treated with NAC in the presence of cysteamine-QDs (net
MFI = 41.5 ± 0.4), suggesting that QD-induced Fas expres-
sion is likely due to QD-mediated oxidative stress.
In addition, free Cd2+ released from QDs and the extent of
QD uptake can contribute to the cell damage and eventu-
ally cell death. We measured intracellular and extracellu-
lar Cd2+ concentrations in SH-SY5Y cell cultures treated
with QDs. Results from this study and from our recently
published study [27] show that Cd2+ concentrations con-
tribute to, but cannot fully explain QD-induced cytotoxic-
ity (31.1 ± 1.7% and 58.0 ± 2.1% cytotoxicity induced by
Cd2+ and QDs respectively), suggesting that impairment
of cellular functions by QDs is multifactorial.
The extent of QD uptake was assessed by FACS analyses.
Cells treated with cysteamine-QDs, NAC-conjugated and
NAC-capped QDs show marked differences in QD uptake.
In particular, cysteamine-QD-treated cells show an evi-
dent shift in fluorescence intensity compared to the
untreated control and to both NAC-conjugated and NAC-
capped QD-treated cells (Figure 3c). Quantitative meas-
urements of the mean fluorescence intensity show that
cysteamine-QDs were indeed taken up most avidly (net
MFI = 17.8 ± 0.1; Figure 3d). On the other hand, NAC-
conjugated QDs (net MFI = 7.3 ± 0.6; p < 0.001) and NAC-
capped QDs (net MFI = 2.1 ± 1.2; p < 0.001) were inter-
nalized significantly less than cysteamine-QDs. The net
MFI for cells pretreated with 2 mM NAC (5.6 ± 0.8; p <
0.001) was significantly lower than in the absence of NAC
(net MFI = 17.8 ± 0.1), suggesting that NAC either reduced
QD uptake or partly quenched QD fluorescence. The lat-
ter is unlikely as spectral data show that these NAC-mod-
ified QDs have comparable, and in some cases even
higher, fluorescence intensities as the unmodified QDs
(see Additional file 1). On the other hand, measurements
of intracellular Cd2+ show reduced Cd2+ content in NAC
pretreated cells, supporting the notion that less QDs were
internalized by the cells and that extracellular Cd2+ effects
were also diminished by NAC.
QD-induced lipid peroxidation and change in membrane 
potential (∆ψm) of the mitochondria
The subcellular distribution of internalized QDs has pre-
viously been reported to induce ROS production and
organelle damage [12,14]. Here we identify two intracel-Journal of Nanobiotechnology 2007, 5:1 http://www.jnanobiotechnology.com/content/5/1/1
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Viability and metabolic activity of human neuroblastoma (SH-SY5Y) cells treated with NAC-modified and unmodified cadmium  telluride QDs Figure 2
Viability and metabolic activity of human neuroblastoma (SH-SY5Y) cells treated with NAC-modified and 
unmodified cadmium telluride QDs. a. Quantum dot toxicity differs depending on their surface modifications by NAC. 
Flow cytometry light scatter dot plots reveal two distinct cell populations corresponding to viable cells (R1), and cells in vari-
ous stages of apoptotic death (R2). FSC, forward scatter (proportional to cell size); SSC, side scatter (proportional to cell com-
plexity or granularity). b. Cell death in neuroblastomas after 24 hours of QD treatments. Graph shows percentage of dead 
cells (gated on R2) for each treatment: Ctrl = cells under serum-deprivation with no drug or QD added; QD = cysteamine-
QDs; NAC-conj QD = NAC-conjugated QDs; NAC-cap QD = NAC-capped QDs; NAC (2 mM); NAC + QD (2 mM NAC + 
5 µg/mL cysteamine-QD). All QDs were added at 5 µg/mL. Mean values and standard deviations from three independent 
experiments (N = 9) are shown. (*p < 0.05; **p < 0.01). c. Mitochondrial metabolic activity was assessed using MTT and its 
conversion to formazan was measured at 595 nm. All values are expressed relative to cells without any drug or QD addition 
(Ctrl) taken as 100%. Note significant decrease with QD treatments and full recovery in the presence of 2 mM NAC. Mean val-
ues and standard deviations from quadruplicate measurements in two independent experiments (N = 8) are shown. (**p < 
0.01).
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Fas expression and internalization of QDs Figure 3
Fas expression and internalization of QDs. a. Exposure to QDs induces cell-surface Fas expression in neuroblastomas. 
Fas expression was assessed by FACS in untreated cells (grey line) and in cells exposed to cysteamine-QDs for 24 hours (black 
line). Dotted line shows background staining of untreated cells with isotype-matched control antibody. b. Net Fas expression 
was calculated as Mean Fluorescence Intensity (MFI) of cells stained with anti-Fas antibodies subtracted by MFI of isotype con-
trol antibody-stained cells. Averages and standard deviations from three independent experiments (N = 9) are shown (*p < 
0.05). c. QD uptake was assessed by flow cytometry in neuroblastoma cells treated with 5 µg/ml QDs (unmodified and NAC-
modified) for 24 hours. d. Net Mean Fluorescence Intensities (MFI) of cells treated with cysteamine-QDs, NAC-conjugated 
and NAC-capped QDs, and cysteamine-QDs in the presence of 2 mM NAC (NAC + QD) are shown. Net MFI was calculated 
as MFI of QD-treated cells subtracted by the autofluorescence of untreated cells. Note a significant decrease (p < 0.05) in the 
MFI of NAC-modified QDs compared with MFI of cysteamine-QDs. Averages and standard deviations from three independent 
experiments (N = 9) are shown (***p < 0.001).
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lular targets of this QD-induced ROS, namely membrane
lipids and mitochondria. In response to oxidative stress,
cell surface and organellar membrane lipids may undergo
peroxidation [24]. We assessed lipid peroxidation by spec-
trofluorometric measurements of the fluorescent BOD-
IPY-C11 dye and by confocal microscopy (Figures 4a, b).
When compared to untreated control cells (100.0 ±
6.3%), cells treated either with cysteamine-QDs (70.2 ±
2.0%, p < 0.01) or NAC-capped QDs (76.6 ± 6.5%, p <
0.05) showed significantly reduced red (non-oxidized) to
green (oxidized) ratios. Cells treated with NAC-conju-
gated QDs or pretreated with free NAC, in the presence of
cysteamine-QDs, did not show significant lipid peroxida-
tion compared to the untreated control.
Double labeling using BODIPY-C11 dye and MitoTracker
Deep Red 633 revealed lipid peroxidation of the mito-
chondrial membranes as shown by confocal microscopy
(Figure 4b). Co-localized oxidized BODIPY-C11(green)
and MitoTracker Deep Red 633 (red-purple) appear as
punctate yellow signals, suggesting local membrane lipid
peroxidation within the mitochondria in cells treated with
QDs.
Membrane lipid peroxidation can produce damaging
aldehydes, and at the mitochondrial level, this can impair
mitochondrial functions [28]. Confocal microscopy anal-
yses of cells stained with JC-1 clearly show that QD-
treated cells have significantly reduced mitochondrial
membrane potential (∆ψm) (Figure 4c). Compared to the
strong red fluorescence of JC-1 aggregates observed in the
untreated control, QD-treated cells show an increased
intensity in green fluorescence (JC-1 monomers) which
correlates with a decrease in ∆ψm.
Discussion
Initial reports on the potential toxicity of some types of
quantum dots (QDs) [13,14,29] prompted the develop-
ment of differently modified QDs as tools in the biologi-
cal sciences. Several studies describing modifications to
improve QD biocompatibility for their broad applica-
tions in the medical sciences were recently reported
[10,30,31]. At the other end of the spectrum, research
groups are also attempting to harness and apply QD tox-
icity in toxicotherapy. For instance, one study proposed
the application of dopamine-conjugated QDs as inducers
of cellular phototoxicity [32], while others are using QDs
in photodynamic therapy [33] and to target different
stages of cancers [11,34]. Using NAC-conjugated, NAC-
capped and cysteamine-capped CdTe QDs, this study
shows several cellular responses of human neuroblastoma
cells to these nanoparticles. Surface-modified nanoparti-
cles with NAC led to reduced cell death, decreased Fas
expression and decreased mitochondrial membrane lipid
peroxidation. The negatively charged NAC-capped QDs
were the most benign, followed by NAC-conjugated QDs.
Cysteamine-QDs, with a net positive surface charge,
showed significant cellular uptake, as well as increased
upregulation of Fas receptors on the cell surface and mem-
brane lipid peroxidation, contributing to the impairment
of mitochondrial and overall cell functions. In addition to
surface charge, cytotoxicity is also affected by other physi-
cochemical properties, including particle size, core-shell
composition and capping [14,35,36].
QD biocompatibility can be easily altered by surface mod-
ifications, such as conjugation and capping with biomol-
ecules and polymers [31,37,38]. The Hoshino group
characterized the physicochemical properties of different
surface-modified CdSe QDs and reported that these sur-
face modifications affect QD surface potential, QD fluo-
rescence and QD-induced cytotoxicity [36]. In our study,
we found that QD surface conjugation and capping with
an antioxidant, N-acetylcysteine (NAC), reduced QD
uptake and cytotoxicity (Figures 2 and 3). Moreover, pre-
treatment of cells with free NAC fully protected cells from
QD-induced cytotoxicity (Figure 2b), as demonstrated in
our previous study in a different cell line [12]. NAC can
protect cells both from apoptosis and necrosis. Mecha-
nisms of the cytoprotective action of NAC are well-docu-
mented, and involve NAC acting (i) as a direct thiol
antioxidant, (ii) as a glutathione precursor, (iii) as a tran-
scription regulator for genes involved in cellular homeos-
tasis, and (iv) as a cell survival promoter via inhibition of
apoptotic pathways including JNK and p38 [26].
Highly metabolically active mitochondria are particularly
sensitive and vulnerable targets to cellular stress [25].
Cells treated with QDs undergo a change in mitochon-
drial membrane potential (∆ψm) (Figure 4c). Membrane
depolarization has been widely associated with the release
of the apoptotic factor, cytochrome c, which amplifies
pro-apoptotic caspase cascades, promoting cell death
[12,25]. Among the regulators of mitochondrial mem-
brane potential, cardiolipin, a mitochondrial membrane
specific lipoprotein, is of particular relevance in neuronal
cells [39,40]. The abundance of cardiolipin in the mem-
branes of the mitochondria maintains the membrane
potential and regulates the release of cytochrome c. Upon
cellular stress, cardiolipin, along with other membrane
lipids, is degraded due to lipid peroxidation, and the
membrane potential is no longer stable, resulting in an
uncontrolled release of mitochondrial content [40,41]. In
addition to causing membrane instability and increasing
the vulnerability of the cell to subsequent insults [28],
lipid peroxidation can also generate harmful and rela-
tively stable aldehyde products which add to the oxidative
stress. One of these damaging aldehydes is 4-oxo-2-none-
nal (ONE), which acts by activation of the p53 signalingJournal of Nanobiotechnology 2007, 5:1 http://www.jnanobiotechnology.com/content/5/1/1
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QD-induced mitochondrial lipid peroxidation and change in membrane potential Figure 4
QD-induced mitochondrial lipid peroxidation and change in membrane potential. a. Spectrofluorometric assess-
ment of lipid membrane peroxidation by ratiometric approach in untreated (Ctrl) or QD-treated cells. The ratio between the 
red and green fluorescence in the control was taken as 100% and all other values with NAC or QD treatments were 
expressed relative to it. All values are means from quadruplicate measurements and are obtained from three independent (N = 
12) experiments (*p < 0.05; **p < 0.01). b. Confocal micrograph showing dual labeling of oxidized lipids (green fluorescence 
from oxidized BODIPY-C11) within mitochondria (labeled with MitoTracker Deep Red 633). Insets show two adjacent cells 
from the same field. Scale bar = 10 µm. c. Confocal micrographs of SH-SY5Y cells labeled with JC-1 reveal decrease in mito-
chondrial membrane potential after QD treatment. Cells were treated with 5 µg/mL QD and typical change in fluorescence 
from red (Em = 590 nm) to green (Em = 530 nm) was assessed in cell cultures in serum-free medium (control) or QD (5 µg/
mL). Note an enhanced intensity of green fluorescence in QD-treated cells. The micrograph illustrates the loss in mitochon-
drial potential upon oxidative stress induced by QDs. Scale bar = 10 µm.
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pathway and induces apoptosis in SH-SY5Y neuroblast-
oma cells [42].
Besides intracellular targeting at the mitochondrial level,
QD treatment leads to an upregulation of cell surface Fas
expression (Figures 3a and 3b). The Fas receptor, when
activated by Fas ligand, associates with FADD which
recruits caspase-8 or caspase-10, and forms the death-
inducing signaling complex (DISC). Caspases-8/10 auto-
catalyze their own cleavage [43-45], triggering a cascade of
caspase activation that culminates in apoptosis. This cas-
cade may be further amplified by cleavage of the caspase-
8/10 substrate Bid, which then inserts into the mitochon-
drial membrane, resulting in loss of ∆ψm and release of
cytochrome c, further accelerating apoptosis. Fas has been
implicated as an inducer of apoptosis under conditions of
high in vivo oxidative stress [46-48], and recent studies
show that Fas expression may also be triggered upon acti-
vation of proapoptotic transcription factors, such as
FOXO3 [49].
Nanoparticles, such as the CdTe QDs investigated here,
enter cells and can get sequestered within different
organelles, changing organellar morphologies and
obstructing their functions, leading eventually to cell
death of different types [17,50,51]. For instance, our
recent study in human breast cancer cells [27] showed
that QDs induce enlargements of lysosomes and mito-
chondria, both of which are morphological indications of
necrotic cell death. On the other hand, intracellular accu-
mulation of unprotected or unstable QDs can eventually
result in QD degradation and Cd2+ release from the QD
core, initiating apoptosis. The extent of apoptosis in neu-
roblastoma cells and Cd2+  released are, however, not
strongly correlated, suggesting additional contributors to
cell death aside from the free Cd2+.
Neuroblastoma cells that were deprived of serum-derived
trophic factors are more susceptible to additional insults
induced by QDs (i.e. ROS, Cd2+), leading to both type I
(apoptosis) and type III (necrosis) cell death [17]. Under
the circumstances in which QDs could be employed for
the detection and elimination of neuroblastoma, one
should bear in mind not only the physical properties of
QDs but also the vulnerability of healthy tissues sur-
rounding the tumour, the rate of QD sequestration and
the rate of metal elimination from the body [51]. Collec-
tively, earlier and current findings suggest that cell pre-
conditioning, combined with modifications of the QD
surface with NAC and a tumour-specific ligand (e.g. Trk
mimetics to target Trk receptors) could yield an improved
nano-oncological therapeutic, sensitizing or diagnostic
agent for neuroblastomas.
Conclusion
Results from this study provide new mechanistic data
(summarized in Figure 5) on the much debated issue of
QD toxicity. Cadmium telluride (CdTe) QD-induced
cytotoxicity depends on multiple QD properties including
QD core size, stability in biological media and surface
chemistry which determine the extent of cellular internal-
ization. Mechanisms of CdTe QD-induced toxicity
include multiple organelle damage and involve increased
Fas receptor expression and cell membrane lipid peroxi-
dation in SH-SY5Y neuroblastoma cells. These damages
bring about cell death both by apoptosis and necrosis.
Understanding the mechanisms underlying QD toxicity is
important as QDs and other nanoparticles are promising
tools in the field of nano-oncology as potential imaging
agents, photosensitizers, biosensors and nanotherapeu-
tics.
Materials and methods
Preparation of CdTe quantum dots
Tellurium powder (200 mesh, 99.8%), sodium borohy-
dride (99%), cadmium perchlorate hydrate, N-acetyl-
cysteine (99%) and cysteamine hydrochloride (98%)
were purchased from Sigma-Aldrich. Milli-Q water (Milli-
pore) was used as a solvent. Photoluminescence measure-
ments were carried out at room temperature using a Cary
Eclipse Fluorescence spectrometer. The excitation wave-
length was set at 400 nm. The excitation and emission slits
were set at 5 nm. Dialysis was performed using spectra/
por molecularporous membrane tubing (Spectrum Labo-
ratories, Inc.) with a 6000–8000 Da molecular weight cut-
off. Centrifugation was performed with Eppendorf
centrifuge 5403 (10,000 rpm) and Eppendorf centrifuge
5415 C (14,000 rpm).
Preparation of Cysteamine capped (+) CdTe
Sodium borohydride (0.8 g, 21.1 mmol) was dissolved in
water (20 mL) at 0°C under N2 atmosphere. Tellurium
powder (1.28 g, 10 mmol) was added portionwise and the
mixture was stirred at 0°C for 8 h under N2 atmosphere.
The reaction mixture was stored at 4°C in the dark and
used in the next step.
The thiol capped-QDs were prepared as described [12].
Briefly, cadmium perchlorate hydrate (500 µL, 1 M aque-
ous solution) and cysteamine hydrochloride (300 mg,
2.64 mmol) were dissolved in 200 mL of N2 saturated
Milli-Q water. The pH of the solution was adjusted to 5.1
with 1N NaOH aqueous solution prior to addition of an
aliquot of the previously prepared NaHTe solution (200
µL). The reaction mixture was heated to reflux for 25 min
under N2. The resulting QD solution was dialyzed against
Milli-Q water for 4 h then concentrated to 15 mL using a
rotary evaporator. QDs were precipitated using MeOH/
CHCl3 (1:1, v/v) then collected by centrifugation. TheJournal of Nanobiotechnology 2007, 5:1 http://www.jnanobiotechnology.com/content/5/1/1
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QDs were washed with MeOH/CHCl3 (1:1, v/v) two times
then dried under vacuum. The QDs were used as solutions
either in deionized water or in PBS buffer.
Preparation of NAC capped (-) CdTe
Cadmium perchlorate hydrate (500 µL, 1 M aqueous solu-
tion) and N-acetylcysteine (400 mg, 2.45 mmol) were dis-
solved in 200 mL of N2 saturated Milli-Q water. The pH of
the solution was adjusted to 10.5 with 1N NaOH aqueous
solution prior to addition of an aliquot of the previously
prepared NaHTe solution (200 µL). The reaction mixture
was heated to reflux for 25 min under N2. The resulting
QD solution was dialyzed against Milli-Q water for 4 h
then processed as above.
Conjugation of NAC to cysteamine capped QD
Solutions of NAC (4 mM) were freshly prepared in water
mixed with cysteamine capped (+) CdTe QD in water (2
mg/mL,  λem = 542 nm) followed by 1-ethyl-3-(3'-
dimethylaminopropyl)carbodiimide (EDC; 12 mg, 77.3
µmol) addition. The reaction mixture was incubated for 3
h at room temperature with occasional shaking. The mix-
ture was purified by dialysis against water for 4 h. The
emission wavelength of the resulting solution was 533
nm. The NAC-conjugated QDs were used as a solution in
water. Zeta potentials of all QD preparations were meas-
ured using Zetasizer Nano ZS (Malvern Instruments,
Worchestershire, UK).
Cell culture and treatments
The human neuroblastoma cell line SH-SY5Y was
obtained from ATCC and cultured (37°C, 5% CO2) in
DMEM medium containing phenol red and 10% FBS
(Gibco, Burlington, ON, Canada). Cells were used at 2–8
passages. For spectrofluorometric and colorimetric assays,
cells were cultured in 24-well plates (Sarstedt, Montreal,
QC, Canada) at a density of 105 cells/cm2.
One hour prior to treatments, medium containing serum
was aspirated, and cells washed with serum free medium.
Fresh serum free medium was added to all wells, includ-
ing the untreated control (Ctrl). An additional set of con-
trol cells, grown in 10% FBS, was used to account for
changes in cell morphology, cell number and metabolic
activity due to the serum withdrawal.
Cells were treated with QDs (5 µg/mL) for different time
periods as specified in individual figure legends. QD solu-
tions (5 µg/mL) were prepared from the stock (2 mg/mL)
by dilution in serum free cell culture medium. Cells were
incubated with QDs for a maximum of 24 h before bio-
chemical analysis or live cell imaging.
NAC was dissolved in PBS (400 mM), and was added to
the culture medium 2 h before QDs. All treatments were
done in triplicates or quadruplicates in three or more
independent experiments.
Flow cytometry in determining cell viability, Fas expression 
and cellular uptake of QDs
SH-SY5Y cells were treated with 5 µg/ml QDs (NAC-mod-
ified and unmodified) and/or 2 mM NAC (as indicated)
for 24 h at 37°C/5% CO2 in media supplemented with
10% FBS. Adherent and non-adherent cells were har-
vested and pooled so as not to lose apoptotic cells which
may have detached from the plastic substrate. Cells were
resuspended at 1 × 106 cells/ml in FACS buffer (PBS + 1 %
FCS). Fas expression was determined by labeling cells
with phycoerythrin (PE) conjugated anti-human Fas/
CD95 (clone DX2, BD Biosciences), and PE conjugated
isotype-matched control antibodies (mouse IgG1 kappa,
BD Biosciences) for 30 min on ice. Cells were washed
twice and resuspended in 300 µl FACS buffer. Samples
analysed for viability and/or for quantum dot-associated
fluorescence alone (FL1, PMT 488–540 nm) were not
labeled with antibodies. 10,000 events per sample were
acquired on a Becton Dickinson FACScan flow cytometer.
Data were analyzed using CellQuest software. Fas expres-
sion was determined as follows: Net Fas expression = Fas
mean fluorescence intensity (MFI) – isotype control MFI
for each individual sample, then averages and standard
deviations of three independent replicates were calcu-
lated.
MTT assay
Colorimetric MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyl tetrazolium bromide, Sigma) assays were per-
formed to assess the mitochondrial activity of cells treated
as described above. After 24 h treatment, media was
removed and replaced with drug-free, serum-free media
(500 µL/well). 50 µL of stock MTT (5 mg/mL) was added
to each well and cells were then incubated for one hour at
37°C. Media were removed, cells were lysed and forma-
zan dissolved with DMSO. Absorbance was measured at
595 nm using a Benchmark microplate reader (Bio-Rad,
Mississauga, ON, Canada). All measurements were done
in triplicates in three or more independent experiments.
Lipid peroxidation
Cells were treated with the fluorescent dye BODIPY 581/
591 C11 (BODIPY-C11, Molecular Probes), which inserts
into lipid membranes and allows for quantitative assess-
ment of oxidized versus non-oxidized lipids by fluoresc-
ing green or red, respectively. Cells were stained for 30
min with a 10 µM solution of BODIPY-C11 prior to QD
treatment. After the QD treatment, lipids were extracted
from the cells according to the Folch method [52] by incu-
bating twice with a mixture of chloroform and methanol
(2:1 (v/v)). After extraction, 0.2 volumes of 0.9% NaCl
solution were added and the chloroform-containingJournal of Nanobiotechnology 2007, 5:1 http://www.jnanobiotechnology.com/content/5/1/1
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phase was collected. After evaporating the chloroform and
dissolving the lipids in isopropanol, spectrofluorometric
readings were taken using the SpectraMax Gemini XS
microplate spectrofluorometer (Molecular Devices Cor-
poration, USA). Data were analyzed using the SOFTmax
Pro 4.0 program. All values are presented as normalized
means ± SEM relative to the respective serum-free control
(taken as 100%).
Confocal microscopy
Images were acquired with a Zeiss LSM 510 NLO inverted
microscope. Cells were grown in 8-well chamber slides
(Lab-Tek, Nalge Nunc International, Rochester, NY, USA).
QDs were added to designated wells and the cells were
incubated for the times indicated. Mitochondria were
stained with MitoTracker Deep Red 633 (1 µM, 1 min,
Molecular Probes; λex 644 nm, λem 665 nm) and imaged
using HeNe 633 nm excitation laser and LP 650 filter.
Lipid peroxidation was visualized using BODIPY-C11
(Molecular Probes; non-oxidized: λex 581 nm, λem 595
nm; oxidized: λex 485 nm, λem 520 nm) with the Argon
488 nm excitation laser and LP 520 nm filter, and the
HeNe 543 nm laser and LP 560 filter. Mitochondrial
depolarization was determined using JC-1 (15 µM, 30
min, Molecular Probes; monomer: λex 485 nm, λem 530
nm; aggregate: λex 535 nm, λem 590 nm). The potential-
sensitive color shift was monitored using the same set of
lasers and filters as BODIPY-C11. Before imaging, cells
were washed with PBS or with serum-free medium. No
background fluorescence of cells was detected under the
settings used. Images were acquired at a resolution of 512
× 512 and 1024 × 1024. Quadruplicate samples were ana-
Proposed mechanism of QD induced cell death involving Fas, lipid peroxidation and mitochondrial impairment Figure 5
Proposed mechanism of QD induced cell death involving Fas, lipid peroxidation and mitochondrial impair-
ment. Cells exposed to cadmium telluride quantum dots (unmodified and NAC-modified) induce ROS which causes Fas 
upregulation and plasma membrane lipid peroxidation. Apoptotic cell death is induced by activation of Fas and its downstream 
effectors. Lipid peroxidation also occurs at the mitochondrial membranes, degrading cardiolipin, changing the mitochondrial 
membrane potential, eventually leading to the release of cytochrome c [12], and promoting apoptotic cascades. NAC bound to 
the QD surface, modifies the extent of QD internalization, which is correlated with cell death, upregulation of Fas, and ROS 
induced lipid peroxidation. NAC treatment (2–5 mM) abolishes oxidative stress, induces antioxidant enzymes and attenuates 
mitochondrial impairment.
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lyzed in all the imaging experiments. Scan size was 146.2
µm × 146.2 µm. Figures were created using Adobe Pho-
toshop.
Statistical analysis
Data were analyzed using SYSTAT 10 (SPSS, Chicago, IL,
USA). Statistical significance was determined by Student's
t-tests with Bonferroni correction. Differences were con-
sidered significant where *p < 0.05, **p < 0.01, ***p <
0.001.
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